Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the efficacy of treating locally advanced pancreatic cancer using Stereotactic Body Radiotherapy (using Trilogy) and Gemcitabine

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Albert Koong
• Treatments: Gemcitabine

Criteria

Inclusion Criteria:- Pancreatic tumors not to exceed 10 cm in greatest axial dimension

• Histologically confirmed malignancies of the pancreas

• Unresectable by CT criteria or exploratory laparotomy or laparoscopy

• Patients with metastatic disease may be treated if they are symptomatic from the primary tumor

• Performance status of 0, 1, or 2

• No chemotherapy two weeks prior or two weeks following radiosurgery

Exclusion Criteria:

• patients who have had prior radiotherapy to upper abdomen

• patients receiving any prior pancreatic cancer therapy

• children, pregnant, and breastfeeding women, and lab personnel are excluded

• uncontrolled intercurrent illnesses

• any concurrent malignancy